Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received an additional supplementary New Drug Application (sNDA) approval from the National Health Insurance Service (NHIS) of South Korea for its drug Xpovio (selinexor). This marks Xpovio as the world’s first and only FDA-approved oral XPO1 inhibitor, now approved for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma (MM) who have received at least one prior treatment.
Previously granted approval in South Korea for combination use with dexamethasone for the treatment of relapsed/refractory MM (R/R MM) in patients who have been treated with at least four prior therapies, and as a monotherapy for recurrent and refractory diffuse large B-cell lymphoma in patients who have undergone at least second-line treatment, Xpovio has further solidified its position in the South Korean market. In July of this year, the drug was included in the medical insurance reimbursement drug list, a first for its class in the country.
The latest approval is expected to broaden patient access to Xpovio, providing an additional treatment option for those living with multiple myeloma in South Korea and highlighting Antengene’s commitment to expanding global access to innovative therapies.- Flcube.com
